ReviewJournal of neurology2015
Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.
Review in Journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Dystonia 3×3: A Training Guideline for Beginners in Botulinum Neurotoxin Treatment of Cervical Dystonia.Toxins · 2026Guideline
- Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications.European journal of neurology · 2025Pooled it
- Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review.Toxins · 2020Pooled it
- Long-Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN-Open-Label Study.Movement disorders clinical practice · 2025Trial
- KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.Brain and behavior · 2022Trial
- Trial
- Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.Journal of neurology · 2018Trial
- Review
- Patient Perceptions of a Preventive Effect of Long-Term Botulinum Neurotoxin Therapy in Cervical Dystonia.Toxins · 2026Article
- Trends and off-label use of botulinum toxin type A in Chinese neurological practice from 2016 to 2023: a real-world study.Frontiers in pharmacology · 2026Article
- Article
- Nationwide Trends in Healthcare Utilization and Expenditures Among Patients with Cervical Dystonia in Korea: A 7-Year Analysis Using Health Insurance Data.Healthcare (Basel, Switzerland) · 2025Article
- Localization modalities for botulinum neurotoxin injection.Toxicon : official journal of the International Society on Toxinology · 2025Review
- Botulinum Toxin for the Treatment of Tremors.Toxins · 2025Review
- Optimal Stimulation Sites and Connectomes for GPi and STN-DBS in Cervical Dystonia.CNS neuroscience & therapeutics · 2025Article
- Article
- Botulinum toxin as a potential adjunct therapy in stiff person syndrome spectrum disorders.Therapeutic advances in neurological disorders · 2025Article
- Comparison of different surgical strategies for cervical dystonia: Evidence from Bayesian network analysis.European journal of neurology · 2025Article
- Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.Toxins · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 14 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.